CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 22.91×, higher than 95% of its Biotechnology peers (median 5.5×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.72BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
106.49%vs all stocks
Market Capitalization
1.72BUSDvs all stocks (USD)
Enterprise Value
1.41BUSDvs all stocks (USD)
Forward P/E
-10.13xvs Biotechnology peers
Price to Book (MRQ)
4.28xvs Biotechnology peers
Enterprise to EBITDA
-6.74xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-49.50%vs Biotechnology peers
Return on Equity (TTM)
-80.95%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-209.47MUSDvs all stocks (USD)
Net Income (TTM)
-199.48MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-163.76MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-95.70MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-169.08MUSDvs all stocks (USD)
Pre-tax Income
-161.15MUSDFY2025 · Dec 31, 2025Net Income
-161.15MUSDFY2025 · Dec 31, 2025EBIT
-169.08MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-168.50MUSDFY2025 · Dec 31, 2025Research & Development
138.35MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
30.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.52MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-161.15MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-125.84MUSDFY2025 · Dec 31, 2025Free Cash Flow
-126.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
46.94MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-161.15MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
578.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.01MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.36MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.38MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.02MUSDFY2025 · Dec 31, 2025Capital Expenditures
-473.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-408.23MUSDFY2025 · Dec 31, 2025Sale of Investments
85.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-323.21MUSDFY2025 · Dec 31, 2025Other Financing Charges
-5.02MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
469.54MUSDFY2025 · Dec 31, 2025Shares Outstanding
45.21MSharesUpdated Jul 19, 2026Float Shares
13.35MSharesUpdated Jul 19, 2026Shares Short
2.58MSharesUpdated Jul 19, 2026Short Ratio
5.58daysvs all stocks
Short % of Shares Outstanding
11.72%vs all stocks
% Held by Insiders
51.16%vs all stocks
% Held by Institutions
56.01%vs all stocks
Total Cash (MRQ)
310.11MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.84USDUpdated Jul 19, 2026Total Debt (MRQ)
5.59MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0140xvs Biotechnology peers
Current Ratio (MRQ)
22.91xvs Biotechnology peers
Book Value per Share (MRQ)
8.84USDUpdated Jul 19, 2026Total Assets
479.51MUSDvs all stocks (USD)
Total Current Assets
324.67MUSDFY2025 · Dec 31, 2025Total Liabilities
21.14MUSDFY2025 · Dec 31, 2025Total Non-current Assets
154.84MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.91MUSDFY2025 · Dec 31, 2025Total Current Liabilities
16.23MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
46.73MUSDFY2025 · Dec 31, 2025Other Short-term Investments
258.37MUSDFY2025 · Dec 31, 2025Accounts Payable
3.29MUSDFY2025 · Dec 31, 2025Short-term Debt
891.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Long-term Debt
4.91MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-360.52MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
458.37MUSDvs all stocks (USD)
52-Week Low
12.24USDUpdated Jul 19, 202652-Week High
40.43USDUpdated Jul 19, 202652-Week Change
106.49%vs all stocks
50-Day MA
31.36USDUpdated Jul 19, 2026200-Day MA
22.62USDUpdated Jul 19, 2026Avg 10-Day Volume
629.61KSharesUpdated Jul 19, 2026Avg 30-Day Volume
531.13KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-4.41USDUpdated Jul 19, 2026Other Income / Expense
2.41MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 22.91×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 22.91Industry median: 5.50Industry P95: 22.03Peers compared: 197
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.72B, above the global median of $1.15BNotable
Market cap (USD): 1,717,240,750Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Butterfly Network Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Sung Kwang Bend Co. Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
EO Technics Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated